2-[(4-chlorophenyl)oxy]-N-[(1R)-1-({[(1-methylcyclopropyl)methyl]oxy}methyl)-2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyridine-3-carboxamide | 1239354-46-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(4-chlorophenyl)oxy]-N-[(1R)-1-({[(1-methylcyclopropyl)methyl]oxy}methyl)-2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyridine-3-carboxamide
• 英文别名: 2-(4-chlorophenoxy)-N-[(2R)-3-[(1-methylcyclopropyl)methoxy]-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl]pyridine-3-carboxamide
• CAS: 1239354-46-1
• 化学式: C₂₅H₃₁ClN₄O₄
• 分子量: 486.999
• InChiKey: AXYNKCHBNQAYEC-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases
  申请人：ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE)

  公开号：US11065238B2

  公开（公告）日：2021-07-20

  The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

  本发明涉及用于治疗运动神经元疾病，特别是遗传性痉挛性截瘫的神经节苷脂代谢抑制剂。
• INHIBITORS OF GANGLIOSIDES METABOLISM FOR THE TREATMENT OF MOTOR NEURON DISEASES
  申请人：ICM - Institut du Cerveau et de la Moelle Epinière

  公开号：EP3534958A1

  公开（公告）日：2019-09-11
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：EXELIXIS INC

  公开号：WO2010091104A1

  公开（公告）日：2010-08-12

  The present invention comprises glucosylceramide synthase (GCS) inhibitors of structural formula (I), and pharmaceutically acceptable salts thereof, wherein R1, E, A, L, X1, Q, R4, R5, m and n, are as defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which GCS is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which GCS is a mediator or is implicated.